Search Results

Press Releases

Wheeler Bio Licenses ATUM’s miFuc™ Technology to Expand Their Portable CMC® Platform Capabilities

September 24, 2024

·

4 min read

Business

ATUM Partners with Anagram Therapeutics to Extend Collaboration to Develop Orally Delivered Enzyme Therapies for Malabsorption and Nutrient Metabolism Disorders

ATUM today announced an expanded partnership with Anagram Therapeutics Inc., a clinical-stage biopharmaceutical company dedicated to improving the lives of people with cystic fibrosis (CF) and other rare diseases.

October 4, 2023

·

4 min read

Biotech Bay

ATUM Announces Leap-In Transposase® Licensing Agreement with Codiak Biosciences to Support Manufacturing of Exosome-Based Therapeutics

ATUM, a global specialist and industry leader in bioengineering solutions, announced the signing of a full licensing agreement for the Leap-In Transposase® technology with Codiak BioSciences, a clinical-stage biopharmaceutical company pioneering the development of exosome-based therapeutics, a new class of medicines.

January 24, 2023

·

3 min read

Biotech Bay

ATUM Partners with TrioBio to Deliver Leap-In Transposase®-Based Bioengineering Solutions to the Chinese Pharmaceutical Market

ATUM announced a distribution partnership with Trio Biotech, Co Ltd. to market and promote ATUM’s unique Leap-In Transposase® platform in China.

April 20, 2022

·

2 min read

BioMidwest

Wheeler Bio Licenses ATUM’s Proprietary Leap-In Transposase® Technology in Support of its Disruptive CDMO Service Offering

Wheeler Bio, Inc., a contract development and manufacturing organization specializing in the development and manufacturing of mammalian-expressed protein therapeutics, announced it has been granted a license to ATUM’s proprietary Leap-In Transposase® and miCHO™ cell line development technology.

November 30, 2022

·

3 min read

Biotech Bay

ATUM’s Leap-In Transposase® Technology Supports Successful AskGene Pharma IND Clearance in China

ATUM’s Leap-In Transposase ® Technology Supports Successful AskGene Pharma IND Clearance in China

October 21, 2021

·

2 min read

Biotech Bay

ATUM Announces Issuance of US Patents Covering Novel Enzymes Critical to Genome Engineering Applications

ATUM, a pioneer in bioengineering solutions, today announced that the United States Patent and Trademark Office (USPTO) has issued patent numbers 11,060,098, 11,060,109, and 11,060,086 which expand the scope of the Leap-In Transposase® platform, the company’s innovative transposon-based tool for genome engineering.

August 11, 2021

·

3 min read

Biotech Bay

Rentschler Biopharma and ATUM Announce Leap-In Transposase® Licensing Agreement for Development of Robust Manufacturing Processes for Complex Therapeutic Proteins

License agreement provides Rentschler Biopharma full access to ATUM’s Leap-In Transposase® cell line development (CLD) tools

October 14, 2020

·

5 min read

Biotech Bay

ATUM and Phylex BioSciences Collaborate to Accelerate the Development of a Universal SARS Coronavirus Vaccine

ATUM and Phylex BioSciences have entered into a collaboration to leverage ATUM’s Leap-In Transposase® platform to develop the cell line essential to the manufacturing of Phylex’s universal SARS coronavirus vaccine candidate.

June 15, 2020

·

2 min read

Business

ATUM and ADM Extend Joint Development Agreement

Bioengineering company ATUM announces today that it has extended its 2014 agreement with Archer Daniels Midland Company (NYSE: ADM) to apply ATUM’s proprietary bioengineering technology and gene engineering platform to ADM’s process technologies.

September 6, 2018

·

2 min read